To Study the Effect of Cenerimod on the Electrical Activity of the Heart, in Men and Women. To Study the Effect of Cenerimod on the Use of Oral Contraceptives in Women. To Study the Effect That Charcoal Has on the Elimination of Cenerimod From the Body, in Women and Men.

A Single-center, Double-blind for Cenerimod, Open-label for Moxifloxacin, Placebo-controlled, Parallel-group, Randomized Study in Healthy Male and Female Subjects to Investigate I: the Effect of Cenerimod on the QTc Interval II: the Effect of Cenerimod on the Pharmacokinetics of Combined Oral Contraceptives III: the Effect of Charcoal on the Pharmacokinetics of Cenerimod.

This is a single-center, randomized, double-blind for cenerimod, open-label for moxifloxacin, placebo- and moxifloxacin-controlled, parallel-group study to investigate the effect of cenerimod on the duration of the QT interval in healthy male and female participants.

Participants will be randomly assigned to one of the 4 treatments: placebo, cenerimod 0.5 mg, cenerimod 4 mg or moxifloxacin.

Study Overview

• Status: Completed
• Conditions: Healthy Subjects
• Intervention / Treatment: Drug: Combined oral contraceptives (COC); Drug: Cenerimod 0.5 mg; Drug: Cenerimod 4 mg; Drug: Moxifloxacin 400mg; Drug: Matching Placebo; Other: Charcoal, activated

Detailed Description

Participants randomized in one of the cenerimod or placebo groups will receive combined oral contraceptives on Day 1 (i.e., prior to cenerimod or placebo administration, Period 1) and on Day 42 (i.e., 36 days after the stat of cenerimod or placebo, Period 2).

Half of the participants randomized in one of the cenerimod or placebo groups will be enrolled in an accelerated elimination procedure part (Period 3).

• Study Type: Interventional
• Enrollment (Actual): 97
• Phase: Phase 1

Contacts and Locations

Study Locations

• France
  • Rennes, France, 35042
    • Site 1

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Signed informed consent in a language understandable to the participant prior to any study-mandated procedure.
• Body mass index of 18.0 to 29.9 kg/m^2 (inclusive) at the screening.
• No clinically relevant findings on the physical examination at screening.
• Systolic blood pressure 90 to 145 mmHg, diastolic blood pressure 45 to 90 mmHg, and pulse rate 50 to 100 bpm (inclusive), measured on the same arm, after 5 min in the supine position at screening and on Day -1.
• 12-lead ECG without clinically relevant abnormalities, measured after 5 min in the supine position at screening and on admission.
• No clinically relevant findings in clinical laboratory tests (hematology, clinical chemistry, and urinalysis) at screening and on admission.
• Negative results from urine drug screen and breath alcohol tests at screening and on admission.
• Women of non-childbearing potential (i.e., postmenopausal [defined as 12 consecutive months with no menses without an alternative medical cause, confirmed by a follicle-stimulating hormone test], with previous bilateral salpingectomy, bilateral salpingo-oophorectomy or hysterectomy, or with premature ovarian failure [confirmed by a specialist]).
• Women of childbearing potential must have a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day -1. They must consistently and correctly use (from screening, during the entire study, and up to end-of-study) a highly effective method of contraception with a failure rate of less than 1% per year (i.e., intrauterine device, bilateral tubal occlusion) or be sexually inactive, or have a vasectomized partner. Hormonal contraceptive must not be used within 3 months prior to screening until end of study visit.

Exclusion Criteria:

• Previous exposure to cenerimod.
• Previous exposure to combined oral contraceptive(s), moxifloxacin, or charcoal within 3 months prior to screening.
• Known hypersensitivity to treatments of the same class as cenerimod, or any of the excipients.
• Known hypersensitivity to combined oral contraceptive(s), moxifloxacin, or charcoal or treatments of the same class, or any of their excipients.
• Any contraindication to combined oral contraceptive(s) or moxifloxacin treatment.
• Known hypersensitivity or allergy to natural rubber latex.
• Lymphopenia (< 1000 cells/μL) at Screening and on Day -1.
• Familial history of sick-sinus syndrome.
• Any cardiac condition or illness (including ECG abnormalities) with a potential to increase the cardiac risk of the subject based on the standard 12-lead ECG at screening.
• History of major medical or surgical disorders which, in the opinion of the investigator, are likely to interfere with the absorption, distribution, metabolism, or excretion of the study treatment (appendectomy and herniotomy allowed, cholecystectomy not allowed).
• Acute, ongoing, recurrent, or chronic systemic disease able to interfere with the evaluation.
• Clinically relevant history of fainting, collapse, syncope, orthostatic hypotension, or vasovagal reactions.
• Any immunosuppressive treatment within 6 weeks or 5 terminal half-lives (t½), whichever is longer, before first study drug administration.
• History or clinical evidence of alcoholism or drug abuse.
• Excessive caffeine consumption, defined as 800 mg or more per day at screening.
• Nicotine consumption within 3 months prior to screening and inability to refrain from nicotine consumption.
• Previous treatment with any prescribed medications (including vaccines) or over-the-counter (OTC) medications (including herbal medicines such as St John's Wort, homeopathic preparations, vitamins, and minerals).
• Viral, fungal, bacterial or protozoal infection and / or serology.
• History of deep vein thrombophlebitis or thromboembolic disorders.
• Legal incapacity or limited legal capacity at screening.
• Pregnant or lactating women.
• History or presence of rhythm disorders (e.g., sinoatrial heart block, sick-sinus syndrome, second- or third-degree atrioventricular block, long QT syndrome, symptomatic bradycardia, atrial flutter, or atrial fibrillation) .

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

9

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: Period 1: First administration of combined oral contraceptives; Participants randomized to placebo or cenerimod will receive a single oral dose of levonorgestrel (100 μg) and ethinylestradiol (20 μg) in the morning on Day 1.	Drug: Combined oral contraceptives (COC); A commercially available COC consisting of 0.1mg levonorgestrel and 0.02 mg ethinylestradiol will be used and administered open-label.; Other Names: Levonorgestrel/Ethinylestradiol
Other: Period 2: Second administration of Combined Oral Contraceptive; Participants randomized to placebo or cenerimod will receive a single oral dose of levonorgestrel (100 μg) and ethinylestradiol (20 μg) in the morning on Day 42.	Drug: Combined oral contraceptives (COC); A commercially available COC consisting of 0.1mg levonorgestrel and 0.02 mg ethinylestradiol will be used and administered open-label.; Other Names: Levonorgestrel/Ethinylestradiol; Drug: Cenerimod 0.5 mg; This will be administered orally as a film-coated tablet in the morning.; Other Names: ACT-334441; Drug: Cenerimod 4 mg; This will be administered orally as a film-coated tablet in the morning.; Other Names: ACT-334441
Experimental: Period 2: Cenerimod 0.5 mg; Participants randomized to cenerimod 0.5 mg will receive a single oral dose in the morning from Day 7 to Day 56.	Drug: Combined oral contraceptives (COC); A commercially available COC consisting of 0.1mg levonorgestrel and 0.02 mg ethinylestradiol will be used and administered open-label.; Other Names: Levonorgestrel/Ethinylestradiol
Experimental: Period 2: Cenerimod 4 mg; Participants randomized to cenerimod 4 mg will receive a single oral dose in the morning from Day 7 to Day 56.	Drug: Combined oral contraceptives (COC); A commercially available COC consisting of 0.1mg levonorgestrel and 0.02 mg ethinylestradiol will be used and administered open-label.; Other Names: Levonorgestrel/Ethinylestradiol
Other: Period 2: Moxifloxacin; Participants randomized to moxifloxacin will receive a single oral 400 mg dose in the morning of Day 42.	Drug: Moxifloxacin 400mg; A commercially available formulation of moxifloxacin 400 mg will be used and administered open-label. All tablets will be from the same batch.
Placebo Comparator: Period 2: Placebo; Participants randomized to placebo will receive a single oral dose of placebo in the morning from Day 7 to Day 56.	Drug: Matching Placebo; Cenerimod matching placebo tablets will be administered once daily orally in the morning.
Experimental: Period 3: Cenerimod 0.5 mg and charcoal; Participants randomized to cenerimod 0.5 mg in Period 2 will receive 50 g of activated charcoal every 12 hours from Day 57 to Day 67.	Drug: Cenerimod 0.5 mg; This will be administered orally as a film-coated tablet in the morning.; Other Names: ACT-334441; Other: Charcoal, activated; Granules for oral suspension will be used and administered open-label.; Other Names: Carbomix 50g
Experimental: Period 3: Cenerimod 4 mg and charcoal; Participants randomized to cenerimod 4 mg in Period 2 will receive 50 g of activated charcoal every 12 hours from Day 57 to Day 67.	Drug: Cenerimod 4 mg; This will be administered orally as a film-coated tablet in the morning.; Other Names: ACT-334441; Other: Charcoal, activated; Granules for oral suspension will be used and administered open-label.; Other Names: Carbomix 50g
No Intervention: Period 3: Cenerimod elimination period; Participants randomized to cenerimod 0.5 mg or 4 mg in Period 2 will receive no treatment (i.e., activated charcoal from Day 57 to Day 67) but will have blood samples taken.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Placebo-corrected, change-from-baseline QTcF (ΔΔQTcF)	ECG variables will be assessed from ECGs extracted in replicates at predefined time points from continuous 24 hour Holter ECG recordings.	Day 6, 7, 14, 21, 35, and 56.
Maximum plasma concentration (Cmax): levonorgestrel	Blood samples for determination of pharmacokinetic parameters will be collected at multiple predefined time points.	Day 1 to Day 3; Day 42 to Day 44
Maximum plasma concentration (Cmax): ethinylestradiol	Blood samples for determination of pharmacokinetic parameters will be collected at multiple predefined time points.	Day 1 to Day 3; Day 42 to Day 44
Time to reach Cmax (tmax): levonorgestrel	Blood samples for determination of pharmacokinetic parameters will be collected at multiple predefined time points.	Day 1 to Day 3; Day 42 to Day 44
Time to reach Cmax (tmax): ethinylestradiol	Blood samples for determination of pharmacokinetic parameters will be collected at multiple predefined time points.	Day 1 to Day 3; Day 42 to Day 44
The area under the plasma concentration-time curve (AUC) from zero to infinity (AUC0-inf): levonorgestrel	Blood samples for determination of pharmacokinetic parameters will be collected at multiple predefined time points.	Day 1 to Day 3; Day 42 to Day 44
The area under the plasma concentration-time curve (AUC) from zero to t (AUC0-t): levonorgestrel	Blood samples for determination of PK parameters will be collected at predefined	Day 1 to Day 3; Day 42 to Day 44
The area under the plasma concentration-time curve (AUC) from zero to infinity (AUC0-inf): ethinylestradiol	Blood samples for determination of pharmacokinetic parameters will be collected at multiple predefined time points.	Day 1 to Day 3; Day 42 to Day 44
The area under the plasma concentration-time curve (AUC) from zero to t (AUC0-t): ethinylestradiol	Blood samples for determination of pharmacokinetic parameters will be collected at multiple predefined time points.	Day 1 to Day 3; Day 42 to Day 44
Terminal elimination half-life (t1/2): levonorgestrel	Blood samples for determination of pharmacokinetic parameters will be collected at multiple predefined time points.	Day 56 to Day 68
Terminal elimination half-life (t1/2): ethinylestradiol	Blood samples for determination of pharmacokinetic parameters will be collected at multiple predefined time points.	Day 56 to Day 68
Terminal elimination half-life (t1/2): cenerimod	Blood samples for determination of pharmacokinetic parameters will be collected at multiple predefined time points.	Day 56 to Day 68
Area under the plasma concentration-time curve (AUC) from Day 56 to infinity (AUC56-inf) for cenerimod	Blood samples for determination of pharmacokinetic parameters will be collected at multiple predefined time points.	Day 56 to Day 68

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from baseline in total lymphocyte count to each time point	Blood samples (fasting) collected at predefined time points as part of the normal hematology analysis.	Day 5, Day 7, Day 14, Day 21, Day 35, Day 56, Day 57, Day 58, Day 1, Day 64, and Day 67
Maximum plasma concentration (Cmax): cenerimod	Blood samples for determination of pharmacokinetic parameters will be collected at multiple predefined time points.	Day 7, Day 14, Day 21, Day 35, and Day 56
Time to reach Cmax (tmax): cenerimod	Blood samples for determination of pharmacokinetic parameters will be collected at multiple predefined time points.	Day 7, Day 14, Day 21, Day 35, and Day 56

Collaborators and Investigators

• Sponsor: Viatris Innovation GmbH
• Investigators: Study Director: Clinical Trials, Viatris Innovation GmbH

Study record dates

Study Major Dates

• Study Start (Actual): January 31, 2020
• Primary Completion (Actual): September 14, 2021
• Study Completion (Actual): October 18, 2021

Study Registration Dates

• First Submitted: January 29, 2020
• First Submitted That Met QC Criteria: February 3, 2020
• First Posted (Actual): February 5, 2020

Study Record Updates

• Last Update Posted (Estimated): September 22, 2025
• Last Update Submitted That Met QC Criteria: September 16, 2025
• Last Verified: November 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Reproductive Control Agents; Contraceptive Agents, Female; Contraceptive Agents; Contraceptives, Oral; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Pharmaceutical Preparations; Pharmacologic Actions; Chemical Actions and Uses; Therapeutic Uses; Polycyclic Compounds; Inorganic Chemicals; Steroids; Fused-Ring Compounds; Elements; Estradiol Congeners; Gonadal Steroid Hormones; Gonadal Hormones; Drug Combinations; Fluoroquinolones; 4-Quinolones; Quinolones; Quinolines; Norpregnenes; Norpregnanes; Norsteroids; Carbon; Norpregnatrienes; Estrogenic Steroids, Alkylated; Norgestrel; Moxifloxacin; Charcoal; Levonorgestrel; Ethinyl Estradiol; Contraceptives, Oral, Combined; cenerimod
• Other Study ID Numbers: ID-064-105; 2019-003156-36 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No